Neuraxpharm

Neuraxpharm company information, Employees & Contact Information

Explore related pages

Related company profiles:

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. To learn more about Neuraxpharm, please visit https://www.neuraxpharm.com

Company Details

Employees
856
Address
Avda. Barcelona, 69, Sant Joan Despí,barcelona 08970,spain
Phone
+49 2173 10600
Email
in****@****harm.de
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Sant Joan Despí, Barcelona
Looking for a particular Neuraxpharm employee's phone or email?

Neuraxpharm Questions

News

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia - Yahoo Finance

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia Yahoo Finance

Sidley Advises Permira and CNS Pharmaceutical Leader Neuraxpharm on €925 Million Refinancing - Sidley Austin LLP

Sidley Advises Permira and CNS Pharmaceutical Leader Neuraxpharm on €925 Million Refinancing Sidley Austin LLP

Permira weighs €4bn exit from Neuraxpharm as CNS drug pipeline builds momentum - Private Equity Insights

Permira weighs €4bn exit from Neuraxpharm as CNS drug pipeline builds momentum Private Equity Insights

Neuraxpharm Expands Multiple Sclerosis Initiatives in Mexico - Mexico Business News

Neuraxpharm Expands Multiple Sclerosis Initiatives in Mexico Mexico Business News

First launch for Neuraxpharm’s Riulvy in Germany - The Pharma Letter

First launch for Neuraxpharm’s Riulvy in Germany The Pharma Letter

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis - Yahoo Finance

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis Yahoo Finance

Permira Is Said to Weigh €3 Billion-Plus Sale of Neuraxpharm - Bloomberg.com

Permira Is Said to Weigh €3 Billion-Plus Sale of Neuraxpharm Bloomberg.com

Neuraxpharm Launches Riulvy for MS Treatment in Germany, Plans EU Expansion - NAVLIN DAILY

Neuraxpharm Launches Riulvy for MS Treatment in Germany, Plans EU Expansion NAVLIN DAILY

Patent case: Biogen MA Inc. vs. Sandoz B.V., Neuraxpharm Pharmaceuticals S.L. and Mylan B.V., Netherlands - Wolters Kluwer

Patent case: Biogen MA Inc. vs. Sandoz B.V., Neuraxpharm Pharmaceuticals S.L. and Mylan B.V., Netherlands Wolters Kluwer

Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for PrBuccolam® in Canada and announces its approval by Health Canada - PR Newswire Canada

Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for PrBuccolam® in Canada and announces its approval by Health Canada PR Newswire Canada

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease - Yahoo Finance

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease Yahoo Finance

NICE endorses Neuraxpharm’s ublituximab for treating MS - PharmaTimes

NICE endorses Neuraxpharm’s ublituximab for treating MS PharmaTimes

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe - Indian Pharma Post

ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe Indian Pharma Post

ZIM Lab and Neuraxpharm announces grant of marketing authorization for "Buprenorphine Sublingual Film" in Europe - Business Standard

ZIM Lab and Neuraxpharm announces grant of marketing authorization for "Buprenorphine Sublingual Film" in Europe Business Standard

HAS Backs Reimbursement for Neuraxpharm’s Briumvi in RRMS with "Important" SMR, Re-evaluation in 5 Years - NAVLIN DAILY

HAS Backs Reimbursement for Neuraxpharm’s Briumvi in RRMS with "Important" SMR, Re-evaluation in 5 Years NAVLIN DAILY

Neuraxpharm buys narcolepsy drugs - The Pharma Letter

Neuraxpharm buys narcolepsy drugs The Pharma Letter

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years - Labiotech.eu

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years Labiotech.eu

Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy - PharmaTimes

Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy PharmaTimes

CNS link-up between Neuraxpharm and Pharmathen - The Pharma Letter

CNS link-up between Neuraxpharm and Pharmathen The Pharma Letter

Veeva Vault Quality Helps Neuraxpharm Drive Seamless Quality Operations and Collaboration With Over 100 CDMOs - Veeva

Veeva Vault Quality Helps Neuraxpharm Drive Seamless Quality Operations and Collaboration With Over 100 CDMOs Veeva

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease - Labiotech.eu

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease Labiotech.eu

Neuraxpharm to commercialize device giving early warning of epileptic seizures - Labiotech.eu

Neuraxpharm to commercialize device giving early warning of epileptic seizures Labiotech.eu

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy) - GlobeNewswire

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy) GlobeNewswire

Neuraxpharm expands into the Middle East - The Pharma Letter

Neuraxpharm expands into the Middle East The Pharma Letter

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment - Labiotech.eu

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment Labiotech.eu

Permira Partnership Series | Neuraxpharm - Permira

Permira Partnership Series | Neuraxpharm Permira

TG shares tumble following licensing deal for MS drug - BioPharma Dive

TG shares tumble following licensing deal for MS drug BioPharma Dive

Neuraxpharm - The Pharma Letter

Neuraxpharm The Pharma Letter

Neuraxpharm to Utilize Veeva Quality Applications - Contract Pharma

Neuraxpharm to Utilize Veeva Quality Applications Contract Pharma

Neuraxpharm steps into the Digital Health market with a wearable device developed by mjn-neuro that provides an early warning of epileptic seizures - Cision News

Neuraxpharm steps into the Digital Health market with a wearable device developed by mjn-neuro that provides an early warning of epileptic seizures Cision News

A Breakthrough in the Global Medical Cannabis Market: Neuraxpharm Enters the Medical Cannabis Market as the First-ever European Pharmaceutical Company to Market Medical Cannabis Products - PR Newswire

A Breakthrough in the Global Medical Cannabis Market: Neuraxpharm Enters the Medical Cannabis Market as the First-ever European Pharmaceutical Company to Market Medical Cannabis Products PR Newswire

Neuraxpharm Expands Presence in Latin America - Mexico Business News

Neuraxpharm Expands Presence in Latin America Mexico Business News

Sanofi, still on CEO Paul Hudson's quest to slim down, offloads 17 drugs to Neuraxpharm - Fierce Pharma

Sanofi, still on CEO Paul Hudson's quest to slim down, offloads 17 drugs to Neuraxpharm Fierce Pharma

-Permira buys German specialty pharma group Neuraxpharm - Reuters

-Permira buys German specialty pharma group Neuraxpharm Reuters

TG taps Neuraxpharm to commercialize MS drug Briumvi overseas in deal worth up to $645M - Fierce Pharma

TG taps Neuraxpharm to commercialize MS drug Briumvi overseas in deal worth up to $645M Fierce Pharma

Neuraxpharm Will Buy Sanofi CNS Portfolios - HealthLeaders Media

Neuraxpharm Will Buy Sanofi CNS Portfolios HealthLeaders Media

Neuraxpharm partners with mjn-neuro on epilepsy wearable - pharmaphorum

Neuraxpharm partners with mjn-neuro on epilepsy wearable pharmaphorum

TG signs $645m deal with Neuraxpharm to support international launch of MS antibody - PMLiVE

TG signs $645m deal with Neuraxpharm to support international launch of MS antibody PMLiVE

Neuraxpharm pays US$650m for MS drug commercialisation - European Biotechnology Magazine

Neuraxpharm pays US$650m for MS drug commercialisation European Biotechnology Magazine

TG Therapeutics Lands Partner to Market MS Drug in Europe and Beyond - MedCity News

TG Therapeutics Lands Partner to Market MS Drug in Europe and Beyond MedCity News

Permira to acquire German pharma firm Neuraxpharm - Pharmaceutical Technology

Permira to acquire German pharma firm Neuraxpharm Pharmaceutical Technology

Backed By Briumvi Collaboration, Neuraxpharm Makes A Base In Middle East - Citeline News & Insights

Backed By Briumvi Collaboration, Neuraxpharm Makes A Base In Middle East Citeline News & Insights

Neuraxpharm CEO Confirms Expansion Into New Markets, Including US - Citeline News & Insights

Neuraxpharm CEO Confirms Expansion Into New Markets, Including US Citeline News & Insights

Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile - Citeline News & Insights

Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile Citeline News & Insights

Neuraxpharm expands its business with Brain Therapeutics buy - The Pharma Letter

Neuraxpharm expands its business with Brain Therapeutics buy The Pharma Letter

Neuraxpharm Targets Austria With Easypharm Deal - Citeline News & Insights

Neuraxpharm Targets Austria With Easypharm Deal Citeline News & Insights

A&O advises Apax Partners and Neuraxpharm on Buccolam acquisition - Iberian Lawyer

A&O advises Apax Partners and Neuraxpharm on Buccolam acquisition Iberian Lawyer

Panaxia and Neuraxpharm expand into Czech and Swiss markets - Business of Cannabis

Panaxia and Neuraxpharm expand into Czech and Swiss markets Business of Cannabis

Neuraxpharm Buccolam Acquisition Opens Up Opportunities - Citeline News & Insights

Neuraxpharm Buccolam Acquisition Opens Up Opportunities Citeline News & Insights

Neuraxpharm turning heads with growth in European CNS market - The Pharma Letter

Neuraxpharm turning heads with growth in European CNS market The Pharma Letter

Neuraxpharm expands Southern European presence with move into Portugal - The Pharma Letter

Neuraxpharm expands Southern European presence with move into Portugal The Pharma Letter

Neuraxpharm expands operations into the Middle East - ZAWYA

Neuraxpharm expands operations into the Middle East ZAWYA

Apax Global Alpha sells Neuraxpharm - QuotedData

Apax Global Alpha sells Neuraxpharm QuotedData

Neuraxpharm to launch its first probiotic product in Europe - Pharmaceutical Business review -

Neuraxpharm to launch its first probiotic product in Europe Pharmaceutical Business review -

First pregabalin tablets in UK launched by Neuraxpharm - Chemist+Druggist

First pregabalin tablets in UK launched by Neuraxpharm Chemist+Druggist

Top Neuraxpharm Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant